pharma · Multiple Sclerosis · Relapsing Remitting Multiple Sclerosis · CTNM
Contineum Therapeutics
Contineum Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker CTNM. Primary therapeutic focus areas include Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Se
San Diego, USA HQ
2017 Founded
59 Employees
Public company Type
CTNM · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2017
- Employees
- 59
- Programs
- 7
- Drugs
- 3
- Patents
- 2
PIPE-791
Phase 1 · small molecule · Idiopathic Pulmonary Fibrosis (IPF)
PIPE-791 for Idiopathic Pulmonary Fibrosis (IPF) is a Phase 1 program (small_molecule) at Contineum Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CTX-791-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Contineum Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Idiopathic Pulmonary Fibrosis (IPF)
- Status
- completed
- Trials
- 1